Benzinga · Mar 12, 2026
SI
NASDAQ · SILO
Silo Pharma, Inc.
Healthcare · Biotechnology
$2.10
Down-$0.01 (-0.47%)
Updated Sep 14, 2026, 4:00 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.54M
- P/E ratio
- -0.82
- Dividend yield
- 0.00%
- 52-week range
- $0.29 – $7.95
- Volume
- 36.76K
- Avg. volume
- 1.27M
Price performance
SILO price history
1M range · 19 trading sessions · Daily adjusted prices
SILO closed at $2.10 after 19 trading sessions, down 31.60% for the selected period.
- Last close
- $2.10
- Period change
- -31.60%
- Period low
- $2.10
- Period high
- $3.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.19 | $2.19 | $2.05 | $2.10 | 36.76K |
| Sep 10, 2026 | $2.18 | $2.39 | $2.10 | $2.1041 | 19.61K |
| Sep 9, 2026 | $2.34 | $2.34 | $2.14 | $2.15 | 39.94K |
| Sep 8, 2026 | $2.33 | $2.3557 | $2.22 | $2.28 | 20.57K |
| Sep 4, 2026 | $2.45 | $2.50 | $2.205 | $2.40 | 35.5K |
| Sep 3, 2026 | $2.51 | $2.54 | $2.37 | $2.45 | 14.97K |
| Sep 2, 2026 | $2.46 | $2.50 | $2.46 | $2.50 | 5.4K |
| Sep 1, 2026 | $2.56 | $2.56 | $2.44 | $2.44 | 7.83K |
| Aug 31, 2026 | $2.48 | $2.55 | $2.47 | $2.48 | 23.02K |
| Aug 28, 2026 | $2.54 | $2.58 | $2.475 | $2.54 | 18.87K |
| Aug 27, 2026 | $2.44 | $2.57 | $2.433 | $2.54 | 18.09K |
| Aug 26, 2026 | $2.59 | $2.7518 | $2.49 | $2.50 | 38.49K |
| Aug 25, 2026 | $2.52 | $2.63 | $2.46 | $2.59 | 56.27K |
| Aug 24, 2026 | $2.64 | $2.732 | $2.501 | $2.58 | 45.5K |
| Aug 21, 2026 | $2.77 | $2.887 | $2.60 | $2.65 | 63.39K |
| Aug 20, 2026 | $2.80 | $2.82 | $2.70 | $2.74 | 32.83K |
| Aug 19, 2026 | $2.68 | $2.91 | $2.58 | $2.86 | 241.51K |
| Aug 18, 2026 | $3.01 | $3.30 | $2.93 | $3.07 | 1.7M |
| Aug 17, 2026 | $3.20 | $3.36 | $2.921 | $3.07 | 50.59K |
Latest SILO news
The latest Smart Investors Daily articles mentioning SILO.
Stock researchCompany · Overview
SILO research
Overview
Company profile and research snapshot.
Company profile
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2023 | Laidlaw & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Silo Pharma shares are trading higher after the company announced a $1 million buyback.
Benzinga · Feb 23, 2026
Silo Pharma Announces $1M Buyback Plan
Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has
Benzinga · Feb 18, 2026
Silo Pharma Gets Notice Of Allowance From Japan Patent Office For Patent Application Covering SPC-15
Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
